Scarica l'app Stockscreener
1.08
3.57%
-0.04
Radiopharm Theranostics Ltd Adr Borsa (RADX) Ultime notizie
Radiopharm Theranostics Files 2026 Annual Report as Nasdaq-Listed Foreign Issuer - TipRanks
Radiopharm Theranostics Files Annual Form 20-F Report with SEC for Fiscal Year Ended 30 June 2026 - Kalkine
Radiopharm Theranostics Shareholders Back Full Suite of Capital Resolutions - TipRanks
OPTH Stock Price, Quote & News - Syfe
Radiopharm Theranostics Reports Promising Phase 1 Imaging Results for RAD301 in Pancreatic Cancer (NASDAQ: RADX) - kalkinemedia.com
Lantheus Entities Hold 20.9% Stake in Radiopharm Theranostics (NASDAQ: RADX) Including Significant Options - Kalkine Media
RADX - Finviz
TRIB Stock Price, Quote & News - Syfe
Radiopharm Theranostics Posts Deeper FY26 Loss as R&D Spend Jumps and Cash Reserves Fall - TipRanks
Radiopharm Theranostics rebuilds its balance sheet as cancer pipeline delivers early trial wins - Kalkine
Radiopharm Theranostics Limited American Depositary Shares (NASDAQ: RADX) Stock Price, News & Analysis - kalkine.ca
Radiopharm Theranostics (RADX) seeks shareholder approval for placements, SPP and new warrants - Stock Titan
Radiopharm Theranostics Limited American Depositary Shares (NASDAQ: RADX) Stock Price, News & Analysis - Kalkine
Radiopharm Theranostics Applies to Quote 408.8 Million Shares from Tranche 1 Australian Placement - Kalkine
Radiopharm Theranostics (RADX) Declines 1.56% as Shares Trade Near Key Support at $2.99Call Dominated - careplusvn.com
Radiopharm Theranostics (RADX) Declines 1.56% as Shares Trade Near Key Support at $2.99Stock Analysis - vinanet.vn
Radiopharm Theranostics (RADX) Declines 1.56% as Shares Trade Near Key Support at $2.99Dealer Gamma - dars.gov.et
Radiopharm Theranostics (RADX) Declines 1.56% as Shares Trade Near Key Support at $2.99Quality Factor - dars.gov.et
Radiopharm Theranostics (RADX) Declines 1.56% as Shares Trade Near Key Support at $2.99Composite Profile - dars.gov.et
Radiopharm Theranostics Reports Business Update - Sahm
Regal Partners' Voting Power in Radiopharm Theranostics Falls to 7.33% After Share Issue - Kalkine
Radiopharm Theranostics Secures Multimillion-Dollar Financings to Advance Oncology Radiopharmaceutical Pipeline - TipRanks
Radiopharm stock tumbles 21% on dilutive capital raise By Investing.com - Investing.com Nigeria
Radiopharm stock tumbles 21% on dilutive capital raise By Investing.com - Investing.com South Africa
Radiopharm Theranostics Raises A$12.5 Million in Institutional Capital as RAD101 Phase 3 Trial Nears Commencement - Kalkine
Radiopharm Theranostics Announces Concurrent US$4.1 Million - GlobeNewswire
Radiopharm stock tumbles 21% on dilutive capital raise - Investing.com
RAD:ASX AnnouncementRAD completes A$12.5 M placement and launches A$6 M SPP24 Jul 2026 - Market Index
Radiopharm Theranostics raises US$4.1M via US o... - Pluang
Radiopharm Theranostics (ASX:RAD) Raises AUD 12.5 Million to Advance Phase 3 Cancer Therapy Program - kalkinemedia.com
Radiopharm raises $8.8 million in U.S. and Australian placements - Investing.com
Radiopharm Theranostics Reports Positive Results from RAD204 and RAD101 Trials - smallcaps.com.au
Radiopharm Theranostics (RADX) Holds Steady Near Support Amid Light TradingOBV Breakout - Vinanet
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Santhera Pharmaceuticals Holding (OtherSPHDF) - The Globe and Mail
Radiopharm Theranostics Limited Financial Disclosures & SEC Filings - TradingView
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) and Senseonics Holdings (SENS) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), TScan Therapeutics (TCRX) and PACS Group Inc (PACS) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Ascentage Pharma Group International (HK:6855), Kiora Pharmaceuticals (KPRX) - The Globe and Mail
Radiopharm Theranostics (RADX) Gains 1.73% as Stock Hovers Above Key Support at $4.13Percent Below MA - po-news-eg.net
Radiopharm Theranostics stock initiated with buy rating at H.C. Wainwright - Investing.com
RADX - Finviz
Radiopharm Theranostics (RADX) Institutional Ownership 2026 - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (ATAI), Immunic (IMUX) and Protara Therapeutics (TARA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Definium Therapeutics (DFTX) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI) - The Globe and Mail
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - GlobeNewswire
1.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):